Suppliers / Shandong Lixin Pharmaceutical

Shandong Lixin Pharmaceutical

China Updated 9 July 2026

Shandong Lixin Pharmaceutical is an API manufacturer based in China. It holds 2 active US drug master files across a filed portfolio of 2 molecules.

2
active US DMFs
0
valid CEPs
1
registered plants 1 with an FDA FEI number
0
filings across 0 regulators
These figures were checked against the regulators' own files on 25 July 2026
Plants
1 of 1 confirmed
Sources: FDA Establishment Registration, read 4 May 2026.

Registered plants

Site FDA FEI
China, China 3017297099

What they file, and where

Molecule Regulators Docs
Molnupiravir US FDA 1
Nilotinib US FDA 1

Also appears on these molecule pages

Molnupiravir API Nilotinib API

Comparing suppliers?

Choose your molecules and target markets. Shandong Lixin Pharmaceutical comes back tiered against every other supplier able to file there.

Start for free
No sales call.

Sources on this page

FDA
Drug master files, establishment registration, inspection classifications
EDQM
Certificates of suitability